Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are condylar head and neck inclinations associated with condylar volume changes following maxillomandibular advancement surgery?

International journal of oral and maxillofacial surgery·2026
Same author

Three-dimensional assessment of temporomandibular joint changes following maxillomandibular advancement surgery: a five-year follow-up study.

International journal of oral and maxillofacial surgery·2024
Same author

Virtual surgical analysis: long-term cone beam computed tomography stability assessment of segmental bimaxillary surgery.

International journal of oral and maxillofacial surgery·2022
Same author

Autotransplantation of premolars: does surgeon experience matter?

International journal of oral and maxillofacial surgery·2018
Same author

Authors' reply to Dr. Sabour.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2017
Same author

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Related Experiment Video

Updated: May 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Dynamic APTT parameters: applications in thrombophilia.

B Sørensen1, J Ingerslev

  • 1Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Guy's and St Thomas' NHS Foundation & King's College London School of Medicine, London, UK. benny.sorensen@kcl.ac.uk

Journal of Thrombosis and Haemostasis : JTH
|December 23, 2011
PubMed
Summary
This summary is machine-generated.

Dynamic activated partial thromboplastin time (APTT) parameters, specifically APTT-MaxVel, show promise in identifying hypercoagulation in patients with venous thrombosis, outperforming standard APTT measurements.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: May 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Area of Science:

  • Hematology
  • Thrombosis Research
  • Clinical Coagulation

Background:

  • Standard activated partial thromboplastin time (APTT) measurements have limited clinical utility in patients with a history of venous thrombosis, despite occasional shortened results.
  • A shortened APTT in thrombosis patients is not a reliable indicator of hypercoagulation.

Purpose of the Study:

  • To characterize dynamic APTT profiles in patients with a history of venous thrombosis.
  • To investigate if APTT-MaxVel is significantly elevated in venous thrombosis patients compared to healthy controls.

Main Methods:

  • A case-control study involving 38 patients with recent venous thrombotic events and 88 healthy controls.
  • Standard APTT was measured in platelet-poor plasma.
  • Digital clotting signals were processed to derive dynamic coagulation parameters, including APTT-MaxVel.

Main Results:

  • Patients with venous thrombosis exhibited significantly higher mean APTT-MaxVel compared to healthy controls.
  • Patients showed significantly shorter mean APTTs than controls.
  • APTT-MaxVel was a more sensitive indicator of hypercoagulation, with 38.5% of patients exceeding the upper reference limit compared to only 2.6% for standard APTT.

Conclusions:

  • Dynamic APTT parameters, particularly APTT-MaxVel, derived from signal processing, offer a stronger predictive marker for hypercoagulation.
  • These dynamic parameters are more effective than standard APTT measurements in identifying hypercoagulation in patients with verified venous thrombosis.